Companion Diagnostics Market Analysis 2026

Market Dynamics

Key Drivers for the Companion Diagnostics Market

• Increasing number of cancer patients is expected to favour market expansion

In recent years, there has been a notable increase in the occurrence of cancer. Effective CDx are becoming more and more necessary as the number of cancer cases rises. This is because genetic testing gives doctors precise information regarding treatment protocols and a clear picture of patients' malignancies. Consequently, the growing incidence of cancer is driving up sales of CDx products. Statistics on cancer in Canada show that 229,200 new cases of cancer were detected in the country in November 2021. Furthermore, 2.26 million new instances of breast cancer and 2.21 million cases of lung cancer were reported globally in 2022, according to the World Health Organization (WHO).
Additionally, in response to a growing demand, innovative tests are being created to identify particular kinds of mutations. The U.S. FDA approved Guardant360 CDx in August 2020.Using Next-Generation Sequencing (NGS) technology, our first liquid biopsy companion diagnostic identifies patients with particular types of mutations of the Epidermal Growth Factor Receptor (EGFR) gene in metastatic Non-Small Cell Lung Cancer (NSCLC).
Moreover, compared to conventional chemotherapy and radiation, targeted medicines offer cancer patients more effective and less hazardous therapeutic options. It is crucial to remember that not all patients respond well to the same targeted medicine, and some may develop resistance over time. To determine which patients will benefit most from a particular targeted medication, companion diagnostics can be used to locate resistance mutations. The increasing prevalence of cancer and the expanding use of targeted therapies are anticipated to fuel the companion diagnostics market's expansion during the forecast period.

• Rising adoption and importance of personalized treatment is elevating the market growth

Personalized medicine is the practice of adjusting medical care to each patient's unique characteristics. Personalized medications are accurate and specially designed for each patient to provide better therapy depending on the body's reaction and susceptibility to illness. Personalized medicine can reduce side effects and costs associated with therapy while simultaneously improving patient outcomes and quality of life. In personalized medicine, companion diagnostics are essential because they help determine the best course of action and dose for each patient based on their genetic profile or expression of biomarkers.
Personalized medicine is not a new idea—it has been used in medical therapy for many years. In fact, its application has grown with time. In recent years, customized medicine has grown at an accelerated rate due to the introduction of new technology. Nonetheless, a long history of scientific study and medical practice forms the basis of these advancements. Therefore, rather than representing a sudden, radical shift in medical practice, customized medicine can be understood as an evolution of it. As new technologies and discoveries are made, the field of customized medicine will continue to advance, building on its foundation of knowledge and technology. (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10058568)
As to the most recent estimates provided by the Personalized Medicine Coalition, individuals with various cancer types, hereditary rare diseases, and a variety of infectious and chronic illnesses can access over 75,000 genetic testing kits and 300 customized medications available in the market.Additionally, companion diagnostics can help monitor response to and resistance to treatment, allowing for any necessary therapy adjustments.

• Growing regulatory acceptance of novel tests for various indications are likely to promote market growth

The companion diagnostics market is seeing a notable increase in the number of newly approved products. A lot of tests are being adopted as a result of the growing number of approved new products, which is fuelling market expansion. Important producers also concentrate on creating new tests that fuel the expansion of the companion diagnostics market. For example, in May 2022, Illumina's TruSight oncology (TSO) complete test was approved by the CE. This test analyses several tumour indicators to pinpoint a cancer patient's unique molecular profile. Additionally, Agilent Technologies Inc. was approved in May 2022 for their qualitative immunohistochemistry assay, PD-L1 IHC 22C3 pharmDx.
Many regulatory agencies, such as the U.S. Food and Drug Administration (FDA), require companion diagnostic tests for the approval of certain targeted therapies. It is necessary to understand companion diagnostic values in order to get regulatory approval for these treatments.

Restraints for the companion diagnostics market

• Expensive immunotherapy treatment is limiting the market growth

Utilizing the body's own immune system, immunotherapy is a treatment strategy that fights cancer. Although immunotherapy has demonstrated significant promise as a cancer treatment, patient access to it has been hampered by its high cost. As an alternative, doctors may combine several therapies, extending the duration of treatment beyond three years, from five months. In this instance, the price rises in direct proportion to the length of time.
Moreover, the cost of customized immunotherapies is expensive. For example, the cost of YESCARTA (produced by Gilead Sciences) and KYMRIAH (developed by Novartis), the approved CAR T-cell therapy, varies from USD 373,000 to USD 475,000 per patient depending on the type of cancer being treated. When considering cancer treatment options, immunotherapies can be far more expensive than chemotherapy or radiation therapy. Therefore, it is anticipated that the enormous costs linked to immuno-oncology treatments will hinder the global market's expansion.

Opportunities for the companion diagnostics market

• Growing need for next-generation sequencing technology

To help advise treatment choices for cancer therapy, NGS-based companion diagnostic tests seek to extract molecular information from each patient's tumour genome. Compared to other sequencing approaches, next-generation sequencing finds many biomarkers for multiple pharmacological treatments faster. Treatment for a wide variety of malignancies may benefit from the use of NGS panels for biomarker measurement in a single test. The different technological developments in NGS also give market participants an instant competitive advantage over those offering other technologies, such PCR, ICH, and ISH. Major industry participants are concentrating on creating companion diagnostic solutions based on NGS as a result.

Impact of COVID-19 on Companion Diagnostics Market

The market for companion diagnostics has been hindered by the development of COVID-19. Due to a drop in testing volume and other variables, major participants in the industry also reported a large loss in revenues as a result of the COVID-19 pandemic. The money generated by the big players decreased significantly in 2020.  However, the revocation of lockdown regulations, the issuance of stay-at-home directives in numerous nations, the introduction of cutting-edge diagnostic tests, and the reconstruction of the supply chain network were crucial elements in the testing rebound in 2021. Thus, the demand in 2021 was positively impacted by the start of cancer diagnostic testing again and the introduction of new diagnostic tests.
Early COVID-19 diagnosis has become crucial in the market since it can help people with the disease receive the right care. The polymerase chain reaction (PCR) test, which uses nasopharyngeal swabs or other upper respiratory tract specimens, such as throat swabs, was the most widely used and trustworthy method for diagnosing COVID-19. Polymerase chain reaction (PCR) diagnosis thereafter became a primary focus for disease management. At that point in the study, SARS-CoV-2 vaccination companion diagnostics provided many important advantages, such as long-term, dependable immune protection through its monitoring with a particular test combination and, as a result, medical security against COVID-19. Consequently, driving market expansion.

Numerous factors are driving the huge expansion of the companion diagnostics market. Rising cancer rates, the development of targeted medicines, and the growing need for individualized medicine are all factors contributing to this trend. When it comes to determining which patients will benefit most from a certain medication, companion diagnostics is essential since it can increase treatment efficacy and minimize side effects. Furthermore, the market is expanding due to the increased emphasis on precision medicine and the growing use of companion diagnostic tests in medication development.

Frequently Asked Questions